SVA Sernova Corp

Sernova Corp. (TSX VENTURE:SVA) is pleased to announce that Mr. Nick Borrelly is
joining Sernova in a consultant corporate development role. Mr. Borrelly has
over 25 years' experience in corporate/business development as well as marketing
and sales in the pharmaceutical (Ciba-Geigy, Novartis and Sanofi-Aventis) and
biopharma industries. As President of Camargue Consulting, he specializes in
development, evaluation and in-licensing of technologies, initiation of
strategic alliances with multi-national corporate partners, and leading sales
and marketing teams for commercial stage products.


"Nick's extensive corporate development network and partnering expertise will be
invaluable to creating significant shareholder value through attracting strong
commercialization partners for our products. As Sernova is now exploring
additional clinical applications of the Cell Pouch(TM), establishing corporate
partners to help accelerate development has become an important part of our
corporate strategy forward", stated Dr. Philip Toleikis, Sernova's President and
CEO.


Mr. Borrelly said, "I am excited to work with Sernova's CEO, Dr. Philip
Toleikis, and his team to fully implement the strategic vision for its
disruptive technologies for the cell-based treatment of chronic diseases." 


Nick's past roles include Manager, Business Development - Licensing &
Acquisitions with Sanofi Aventis Pharma Canada; Vice President, Business
Development for MNLpharma (U.K.) Ltd.; and Vice President, Business Development
for CV Technologies/Afexa Life Sciences Inc. As a Director with Nucleus
BioScience Inc., he coordinated its amalgamation with Stratos BioSciences Inc.
and Brightwave Technologies Inc. to create SNB Capital Corp., which subsequently
took the biotherapeutics company Protox Therapeutics Inc. (now Sophiris Bio Inc)
public in 2004. Nick is currently a member of the Board of Directors of Eternity
Healthcare, and Auxellence Health Corporation.


About Sernova 

Sernova Corp is a clinical stage regenerative medicine company developing
medical technologies for the treatment of chronic debilitating metabolic
diseases such as diabetes, blood disorders including haemophilia and other
diseases treated through replacement of proteins or hormones missing or in short
supply within the body. Sernova is developing the Cell Pouch(TM), an implantable
medical device for therapeutic cells (donor, xenogeneic or stem cells) which
then release proteins and/or hormones as required. The therapeutic cells are
protected from immune attack by Sernova's proprietary local immune protection
technologies. 


Forward Looking Information 

This release may contain forward-looking statements. Forward-looking statements
are statements that are not historical facts and are generally, but not always,
identified by the words "expects", "plans", "anticipates", "believes",
"intends", "estimates", "projects", "potential" and similar expressions, or that
events or conditions "will", "would", "may", "could" or "should" occur. Although
Sernova believes the expectations expressed in such forward-looking statements
are based on reasonable assumptions, such statements are not guarantees of
future performance and actual results may differ materially from those in
forward looking statements. Forward-looking statements are based on the beliefs,
estimates and opinions of Sernova's management on the date such statements were
made. Sernova expressly disclaims any intention or obligation to update or
revise any forward-looking statements whether as a result of new information,
future events or otherwise.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Philip Toleikis, Ph.D., President and CEO
Tel: (604) 961-2939
philip.toleikis@sernova.com
info@sernova.com
www.sernova.com


Ray Matthews & Associates
Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6
Tel: (604) 818-7778
www.raymatthews.ca

Sernova (TSXV:SVA)
Historical Stock Chart
From Jan 2025 to Feb 2025

Sernova (TSXV:SVA)
Historical Stock Chart
From Feb 2024 to Feb 2025